Myocardial fibrosis, the silent instigator of diastolic dysfunction in patients with rheumatoid arthritis.

Physiol Res

Faculty of Medicine, Comenius University in Bratislava, and Fifth Department of Internal Medicine, University Hospital Bratislava, Ružinov, Bratislava, Slovak Republic.

Published: July 2025


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease associated with increased cardiovascular morbidity and mortality. Myocardial fibrosis, a key pathological consequence of prolonged inflammation, contributes to diastolic dysfunction and the development of heart failure with preserved ejection fraction (HFpEF) in RA patients. Understanding its pathophysiology, early detection, and potential therapeutic strategies is crucial for improving patient outcomes. In this study we explore the underlying mechanisms of myocardial fibrosis in RA, focusing on immune-mediated pathways, oxidative stress, and extracellular matrix dysregulation, with concise look at the impact of immunosuppressive therapy on cardiac remodeling and role of speckle-tracking echocardiography (STE) in detecting subclinical myocardial fibrosis, emphasizing global longitudinal strain (GLS) as a promising surrogate marker. Key words Rheumatoid arthritis " Myocardial fibrosis " Diastolic dysfunction " Cardiovascular disease surveillance " Strain echocardiography.

Download full-text PDF

Source

Publication Analysis

Top Keywords

myocardial fibrosis
20
diastolic dysfunction
12
rheumatoid arthritis
12
myocardial
5
fibrosis silent
4
silent instigator
4
instigator diastolic
4
dysfunction patients
4
patients rheumatoid
4
arthritis rheumatoid
4

Similar Publications

Daucosterol ameliorates acute inflammation and fibrosis following myocardial infarction via regulation of the ZBTB16 protein.

Br J Pharmacol

September 2025

Department of Cardiology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China.

Background And Purpose: Myocardial infarction (MI) is accompanied by acute release of numerous inflammatory factors, leading to fibrosis and ultimately cardiac dysfunction. Daucosterol (DAU), a natural sterol compound, has been demonstrated to have anti-inflammatory properties and the ability to mitigate liver fibrosis. This study aims to investigate the therapeutic potential of DAU in MI and explores the underlying mechanisms.

View Article and Find Full Text PDF

In cardiovascular research, melatonin has shown promise in exhibiting antifibrotic properties and modulating endoplasmic reticulum (ER) stress. However, the exact mechanism by which it influences myocardial fibrosis has not been fully clarified. Therefore, this research aimed to investigate the inhibitory effect of melatonin on the progression of myocardial fibrosis through a mechanism involving the BIP/PERK/CHOP signaling pathway, both in silico and in vivo experimental models.

View Article and Find Full Text PDF

Oxidative stress and ferroptosis in diabetic cardiomyopathy: mechanistic interplay and therapeutic implications.

Apoptosis

September 2025

The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, 182 Chunhui Road, Longmatan District, Luzhou, 646000, China.

Diabetic cardiomyopathy (DCM) is a severe cardiovascular complication of diabetes mellitus, characterized by pathological changes such as cardiomyocyte hypertrophy, necrosis, and myocardial fibrosis, which can ultimately lead to heart failure. However, its underlying mechanisms remain incompletely understood, limiting the development of effective therapeutic approaches. In recent years, the critical roles of oxidative stress and ferroptosis in the pathogenesis of DCM have attracted increasing attention.

View Article and Find Full Text PDF

Introduction: Whilst aortic stenosis remains the most prevalent valvular abnormality, the management of asymptomatic severe aortic stenosis remains a clinical challenge. Recently, two randomised-controlled trials (RCTs) - EVOLVED (Early Intervention in Patients With Asymptomatic Severe Aortic Stenosis and Myocardial Fibrosis) and Early TAVR (Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis) - have been published, alongside an extended follow-up from the AVATAR (Aortic Valve Replacement Versus Conservative Treatment in Asymptomatic Severe Aortic Stenosis) study.

Evidence Acquisition: In response, we conducted a systematic review of PubMed, Ovid, and Cochrane databases, identifying RCTs up to October 29, 2024, that compared early intervention with conventional management.

View Article and Find Full Text PDF

Myocardial fibrosis, a key pathological feature of hypertensive heart disease (HHD), remains diagnostically challenging due to limited clinical tools. In this study, a FAPI-targeted uptake mechanism previously reported by our group, originally developed for tumor imaging, is extended to the detection of myocardial fibrosis in HHD using [F]F-NOTA-FAPI-MB. The diagnostic performance of this tracer is compared with those of [F]F-FDG, [F]F-FAPI-42, and [F]F-NOTA-FAP2286, and its potential for fluorescence imaging is also evaluated.

View Article and Find Full Text PDF